Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.

Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H.

J Med Chem. 2019 Apr 11;62(7):3407-3427. doi: 10.1021/acs.jmedchem.8b01888. Epub 2019 Apr 1.

PMID:
30883102
2.

Meeting report of the 14th Japan-Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine.

Sueoka E, Watanabe T, Mashima T, Shirakami Y, Komori A, Matsuo K, Yoshikawa HY, Cho KA, Park TJ, Seimiya H, Kim EG, Suganuma M, Chung J.

J Cancer Res Clin Oncol. 2019 May;145(5):1263-1271. doi: 10.1007/s00432-019-02887-2. Epub 2019 Mar 11.

PMID:
30859317
3.

A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.

Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K.

Invest New Drugs. 2019 Mar 6. doi: 10.1007/s10637-019-00749-9. [Epub ahead of print]

PMID:
30838483
4.

Revisiting Telomere Shortening in Cancer.

Okamoto K, Seimiya H.

Cells. 2019 Jan 31;8(2). pii: E107. doi: 10.3390/cells8020107. Review.

5.

MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs.

Okamoto K, Ohishi T, Kuroiwa M, Iemura SI, Natsume T, Seimiya H.

Oncotarget. 2018 Nov 9;9(88):35844-35855. doi: 10.18632/oncotarget.26312. eCollection 2018 Nov 9.

6.

Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B.

Hatta T, Iemura SI, Ohishi T, Nakayama H, Seimiya H, Yasuda T, Iizuka K, Fukuda M, Takeda J, Natsume T, Horikawa Y.

Sci Rep. 2018 Nov 13;8(1):16756. doi: 10.1038/s41598-018-35204-x.

7.

Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells.

Fujiwara C, Muramatsu Y, Nishii M, Tokunaka K, Tahara H, Ueno M, Yamori T, Sugimoto Y, Seimiya H.

Sci Rep. 2018 Oct 4;8(1):14827. doi: 10.1038/s41598-018-33139-x.

8.

RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.

Mizutani A, Yashiroda Y, Muramatsu Y, Yoshida H, Chikada T, Tsumura T, Okue M, Shirai F, Fukami T, Yoshida M, Seimiya H.

Cancer Sci. 2018 Dec;109(12):4003-4014. doi: 10.1111/cas.13805. Epub 2018 Oct 20.

9.

Development of G-quadruplex ligands for selective induction of a parallel-type topology.

Ma Y, Tsushima Y, Sakuma M, Sasaki S, Iida K, Okabe S, Seimiya H, Hirokawa T, Nagasawa K.

Org Biomol Chem. 2018 Oct 17;16(40):7375-7382. doi: 10.1039/c8ob01702f.

PMID:
30187070
10.

Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole.

Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H.

Sci Rep. 2017 Jun 15;7(1):3605. doi: 10.1038/s41598-017-03785-8.

11.

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.

Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, Sato A, Tanaka N, Sugimoto Y, Seimiya H.

Oncotarget. 2017 Jul 18;8(29):47902-47915. doi: 10.18632/oncotarget.18146.

12.

Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer.

Migita T, Ueda A, Ohishi T, Hatano M, Seimiya H, Horiguchi SI, Koga F, Shibasaki F.

Lab Invest. 2017 Feb 27. doi: 10.1038/labinvest.2017.17. [Epub ahead of print]

13.

Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion.

Ohishi T, Yoshida H, Katori M, Migita T, Muramatsu Y, Miyake M, Ishikawa Y, Saiura A, Iemura SI, Natsume T, Seimiya H.

Cancer Res. 2017 May 1;77(9):2328-2338. doi: 10.1158/0008-5472.CAN-16-1846. Epub 2017 Feb 15.

14.

APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.

Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, Yoshida H, Muramatsu Y, Nakata K, Matsuura M, Katayama R, Nagayama S, Fujita N, Sugimoto Y, Seimiya H.

Mol Cancer Ther. 2017 Apr;16(4):752-762. doi: 10.1158/1535-7163.MCT-16-0578. Epub 2017 Feb 8.

15.

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.

Oncotarget. 2016 Jun 7;7(23):34811-23. doi: 10.18632/oncotarget.9187.

16.

Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.

Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T.

Cancer Sci. 2016 Feb;107(2):189-202. doi: 10.1111/cas.12857. Review.

17.

G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells.

Hasegawa D, Okabe S, Okamoto K, Nakano I, Shin-ya K, Seimiya H.

Biochem Biophys Res Commun. 2016 Feb 26;471(1):75-81. doi: 10.1016/j.bbrc.2016.01.176. Epub 2016 Feb 1.

18.

Senescence from glioma stem cell differentiation promotes tumor growth.

Ouchi R, Okabe S, Migita T, Nakano I, Seimiya H.

Biochem Biophys Res Commun. 2016 Feb 5;470(2):275-281. doi: 10.1016/j.bbrc.2016.01.071. Epub 2016 Jan 14.

19.

Predicting Risk at the End of the End: Telomere G-tail as a Biomarker.

Seimiya H.

EBioMedicine. 2015 Jul 4;2(8):804-5. doi: 10.1016/j.ebiom.2015.07.006. eCollection 2015 Aug. Review. No abstract available.

20.

[Cancer therapy by PARP inhibitors].

Seimiya H.

Nihon Rinsho. 2015 Aug;73(8):1330-5. Review. Japanese.

PMID:
26281686

Supplemental Content

Loading ...
Support Center